{"id":289,"date":"2012-04-11T06:25:00","date_gmt":"2012-04-11T06:25:00","guid":{"rendered":"https:\/\/nolato.wpengine.com\/?mfn_news=nolato-acquires-cope-allman-jaycare"},"modified":"2012-04-11T06:25:00","modified_gmt":"2012-04-11T06:25:00","slug":"nolato-acquires-cope-allman-jaycare","status":"publish","type":"mfn_news","link":"https:\/\/temporary.nolato.com\/sv\/mfn_news\/nolato-acquires-cope-allman-jaycare\/","title":{"rendered":"Nolato acquires Cope Allman Jaycare"},"content":{"rendered":"
Acquisition of British pharmaceutical packaging company
\nresults in a stronger customer base and geographic expansion for Nolato Medical<\/strong><\/div>\n

As part of the Nolato Group\u2019s strategic expansion within medical technology and pharmaceuticals, Nolato has acquired the British company Cope Allman Jaycare for an initial purchase price of SEK 179 million (enterprise value) and a deferred consideration based on earnings up to and including the first quarter of 2014.<\/span><\/p>\n

Cope Allman Jaycare, which manufactures plastic pharmaceutical packaging, has annual sales of around SEK 270 million. Its customers include a number of major international pharmaceutical companies. The company will be consolidated from 1 April, and will have a positive effect on Nolato\u2019s earnings per share 2012.<\/span><\/p>\n

\u201cFollowing the acquisition of the US company Contour Plastics, we have worked to add an acquisition in Western Europe,\u201d says Hans Porat, President and CEO of Nolato. \u201cCope Allman Jaycare is a well-managed company, and is a good fit for our growth strategy.\u201d<\/span><\/p>\n

Cope Allman Jaycare has a history within pharmaceutical packaging dating back to 1958, and is expected to record sales for 2012 of around SEK 270 million, with a pro forma EBITDA margin of approximately 14%. The company has 270 employees at its plants in Portsmouth and Newcastle, England.<\/span><\/p>\n

\u201cNolato already has a strong position in the Scandinavian pharmaceutical packaging market,\u201d adds Christer Wahlquist, President of Nolato Medical. \u201cThis acquisition gives us a local presence in the UK, which is an important part of the global pharma\u00adceutical industry. It also opens doors with a large number of leading international pharmaceutical companies which are existing customers of Cope Allman Jaycare.\u201d<\/span><\/p>\n

The company is being acquired from its current management, which will remain with the business.<\/span><\/p>\n

Following the acquisition, Nolato will continue to have a strong financial position, with an equity\/assets ratio of approximately 47%.<\/span><\/p>\n<\/p>\n

—–
<\/span><\/p>\n

For further information, please contact:<\/span>
Hans Porat, CEO, +46 431 442294<\/span>
Per-Ola Holmstr\u00f6m, CFO, +46 431 442293<\/span><\/p>\n

The Nolato Group is a high-tech developer and manufacturer of polymer product systems for leading customers in medical technology, telecom, hygiene, automotive products and other \u00adselected industrial sectors. Nolato\u2019s shares are quoted on the Nasdaq OMX Nordic Exchange, Stockholm Mid Cap, Industrials.\u00a0 <\/em>www.nolato.com<\/em><\/span><\/p>\n

Nolato AB discloses the information provided herein pursuant to the Securities Markets Act and\/or the Financial Instruments Trading Act. The information was submitted for publication at 8.25 am on 11 April 2012.<\/em><\/span><\/p>\n

\n

<\/strong><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Acquisition of British pharmaceutical packaging company results in a stronger customer base and geographic expansion for Nolato Medical<\/p>\n","protected":false},"template":"","class_list":["post-289","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ca","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-regulatory-listing","mfn-news-tag-mfn-ca-ma","mfn-news-tag-mfn","mfn-news-tag-mfn-regulatory","entry"],"translation":{"provider":"WPGlobus","version":"3.0.0","language":"sv","enabled_languages":["en","es","de","fr","ru","sv"],"languages":{"en":{"title":true,"content":true,"excerpt":true},"es":{"title":false,"content":false,"excerpt":false},"de":{"title":false,"content":false,"excerpt":false},"fr":{"title":false,"content":false,"excerpt":false},"ru":{"title":false,"content":false,"excerpt":false},"sv":{"title":false,"content":false,"excerpt":false}}},"_links":{"self":[{"href":"https:\/\/temporary.nolato.com\/sv\/wp-json\/wp\/v2\/mfn_news\/289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/temporary.nolato.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/temporary.nolato.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/temporary.nolato.com\/sv\/wp-json\/wp\/v2\/media?parent=289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}